Liver Cancer Therapeutics Global Market Report 2025

Description

Liver cancer therapeutics involve a range of treatments designed to manage abnormal cell growth in the liver, a vital organ responsible for essential metabolic and detoxification functions. These therapies aim to target, control, or eradicate harmful cellular activity while preserving as much healthy tissue as possible.

The main types of liver cancer therapeutics include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other liver cancers. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, originating in the liver's hepatocytes (the primary liver cells). It is a leading cause of cancer-related deaths worldwide, especially in regions with high rates of chronic liver diseases including hepatitis B, hepatitis C, alcohol-related liver disease, and cirrhosis (liver scarring). Treatments for HCC include targeted therapy, immunotherapy, chemotherapy, radiation therapy, and others. These therapies are available through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of patients, including both adults and children.

The liver cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver cancer therapeutics market statistics, including liver cancer therapeutics industry global market size, regional shares, competitors with a liver cancer therapeutics market share, detailed liver cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer therapeutics industry. This liver cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer therapeutics market size has grown rapidly in recent years. It will grow from $2.52 billion in 2024 to $2.95 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth observed in the historical period can be attributed to higher funding from government and non-profit organizations, rising global healthcare spending, expanding health insurance coverage in developing nations, an aging global population, and the increasing prevalence of obesity and diabetes.

The liver cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.50 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth projected for the forecast period can be attributed to the increasing global incidence of liver cancer, the high prevalence of hepatitis B and C infections, the rise in alcohol-related liver disease, a growing number of non-alcoholic fatty liver disease cases, and the expanding adoption of immunotherapy approaches. Key trends in the forecast period include the integration of AI and ML in drug discovery, the use of big data and real-world evidence in clinical trials, advancements in imaging technologies, the adoption of minimally invasive diagnostic tools, and the use of telemedicine and digital health in oncology follow-up care.

The increasing incidence of hepatitis B infections is expected to drive the growth of the liver cancer therapeutics market. Hepatitis B is a viral disease caused by the hepatitis B virus (HBV), primarily affecting the liver and potentially leading to both acute and chronic health issues, including liver cancer. The rise in hepatitis B infections is partially fueled by the growing use of injection drugs, which spread the virus through the sharing of contaminated needles and syringes. Liver cancer therapeutics are essential for managing hepatitis B infections, as chronic infection can result in ongoing liver inflammation and cellular damage, significantly raising the risk of malignant liver conditions over time. For example, a report published by the World Health Organization (WHO) in April 2024 indicated that in 2022, over 254 million people globally were living with hepatitis B, with 1.2 million new cases recorded. Hepatitis B was also responsible for 83% of the 1.3 million viral hepatitis-related deaths worldwide. Consequently, the rising incidence of hepatitis B infections will accelerate the growth of the liver cancer therapeutics market.

Innovative therapies are driving growth in the liver cancer treatment market, particularly through advancements in immunotherapy. Leading companies in the liver cancer therapeutics market are focusing on developing cutting-edge treatments, such as prescription immunotherapy drugs, to offer long-lasting effects. These medications work by enhancing or suppressing the body's immune system to fight specific diseases, including cancer or chronic infections, by targeting and modulating immune responses. For example, in April 2025, Bristol Myers Squibb, a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Opdivo (nivolumab) and Yervoy (ipilimumab) for adult patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer, either incurable or metastatic, as a first-line treatment. The approval was based on the results of the global Phase 3 randomized, open-label CheckMate-9DW trial, which showed that patients with metastatic or incurable HCC who had not previously received systemic therapy and were randomized to receive Opdivo plus Yervoy along with a tyrosine kinase inhibitor (lenvatinib or sorafenib) experienced statistically significant improvements in overall survival (OS) and overall response rate (ORR) compared to the comparator group. This combination therapy was the only one supporting an FDA approval with superior results in this setting.

In September 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition strengthens Coherus' immuno-oncology pipeline, which now includes four distinct clinical-stage assets toripalimab (anti-PD-1), casdozokitug (IL-27-targeted), CHS-114 (CCR8-targeted), and CHS-006 (TIGIT-targeted). The focus of development will be on achieving breakthrough survival benefits for cancer patients, aiming to surpass the efficacy of current chemotherapy combined with checkpoint inhibitor regimens. Surface Oncology Inc. is a US-based company, focusing on developing therapeutics for liver cancer.

Major players in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, and Onyx Pharmaceuticals Inc.

North America was the largest region in the liver cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the liver cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver cancer therapeutics market consists of revenues earned by entities by providing services such as diagnostics and screening, personalized treatment planning, minimally invasive procedures, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer therapeutics market also includes sales of drug delivery systems, diagnostic kits, biologics and supportive medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Hepatocellular Carcinoma; Cholangio Carcinoma; Hepatoblastoma; Other Types
2) By Therapy Type: Targeted Therapy; Immunotherapy; Chemotherapy; Radiation Therapy; Other Therapy Types
3) By Distribution Channel Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End-Users: Pediatrics; Adults
Subsegments:
1) By Hepatocellular Carcinoma: Localized Hepatocellular Carcinoma; Advanced Hepatocellular Carcinoma; Recurrent Hepatocellular Carcinoma
2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma
3) By Hepatoblastoma: Standard-Risk Hepatoblastoma; High-Risk Hepatoblastoma; Metastatic Hepatoblastoma
4) By Other Types: Fibrolamellar Carcinoma; Angiosarcoma Of The Liver; Hemangiosarcoma
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35474

1. Executive Summary

2. Liver Cancer Therapeutics Market Characteristics

3. Liver Cancer Therapeutics Market Trends And Strategies

4. Liver Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Liver Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Liver Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Liver Cancer Therapeutics Market Growth Rate Analysis
5.4. Global Liver Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Liver Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Liver Cancer Therapeutics Total Addressable Market (TAM)

6. Liver Cancer Therapeutics Market Segmentation

6.1. Global Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types
6.2. Global Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Immunotherapy
Chemotherapy
Radiation Therapy
Other Therapy Types
6.3. Global Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Liver Cancer Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatrics
Adults
6.5. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Hepatocellular Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Localized Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Recurrent Hepatocellular Carcinoma
6.6. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Cholangiocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intrahepatic Cholangiocarcinoma
Extrahepatic Cholangiocarcinoma
Perihilar Cholangiocarcinoma
6.7. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Hepatoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Standard-Risk Hepatoblastoma
High-Risk Hepatoblastoma
Metastatic Hepatoblastoma
6.8. Global Liver Cancer Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fibrolamellar Carcinoma
Angiosarcoma Of The Liver
Hemangiosarcoma

7. Liver Cancer Therapeutics Market Regional And Country Analysis

7.1. Global Liver Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Liver Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liver Cancer Therapeutics Market

8.1. Asia-Pacific Liver Cancer Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liver Cancer Therapeutics Market

9.1. China Liver Cancer Therapeutics Market Overview
9.2. China Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liver Cancer Therapeutics Market

10.1. India Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liver Cancer Therapeutics Market

11.1. Japan Liver Cancer Therapeutics Market Overview
11.2. Japan Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liver Cancer Therapeutics Market

12.1. Australia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liver Cancer Therapeutics Market

13.1. Indonesia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liver Cancer Therapeutics Market

14.1. South Korea Liver Cancer Therapeutics Market Overview
14.2. South Korea Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liver Cancer Therapeutics Market

15.1. Western Europe Liver Cancer Therapeutics Market Overview
15.2. Western Europe Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liver Cancer Therapeutics Market

16.1. UK Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liver Cancer Therapeutics Market

17.1. Germany Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liver Cancer Therapeutics Market

18.1. France Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liver Cancer Therapeutics Market

19.1. Italy Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liver Cancer Therapeutics Market

20.1. Spain Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liver Cancer Therapeutics Market

21.1. Eastern Europe Liver Cancer Therapeutics Market Overview
21.2. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liver Cancer Therapeutics Market

22.1. Russia Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liver Cancer Therapeutics Market

23.1. North America Liver Cancer Therapeutics Market Overview
23.2. North America Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liver Cancer Therapeutics Market

24.1. USA Liver Cancer Therapeutics Market Overview
24.2. USA Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liver Cancer Therapeutics Market

25.1. Canada Liver Cancer Therapeutics Market Overview
25.2. Canada Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liver Cancer Therapeutics Market

26.1. South America Liver Cancer Therapeutics Market Overview
26.2. South America Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liver Cancer Therapeutics Market

27.1. Brazil Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liver Cancer Therapeutics Market

28.1. Middle East Liver Cancer Therapeutics Market Overview
28.2. Middle East Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liver Cancer Therapeutics Market

29.1. Africa Liver Cancer Therapeutics Market Overview
29.2. Africa Liver Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Liver Cancer Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Liver Cancer Therapeutics Market, Segmentation By Distribution Channel Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liver Cancer Therapeutics Market Competitive Landscape And Company Profiles

30.1. Liver Cancer Therapeutics Market Competitive Landscape
30.2. Liver Cancer Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Liver Cancer Therapeutics Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Bristol-Myers Squibb
31.3. AstraZeneca PLC
31.4. Amgen Inc.
31.5. Eli Lilly and Company
31.6. Gilead Sciences Inc.
31.7. Regeneron Pharmaceuticals Inc.
31.8. Eisai Co. Ltd.
31.9. Ipsen
31.10. Exelixis Inc.
31.11. BeiGene Ltd.
31.12. Hutchmed
31.13. Celgene Corporation
31.14. Zymeworks Inc.
31.15. Can-Fite BioPharma

32. Global Liver Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liver Cancer Therapeutics Market

34. Recent Developments In The Liver Cancer Therapeutics Market

35. Liver Cancer Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Liver Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Liver Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Liver Cancer Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer